Dr Alan Hakim

Based in London, Dr Hakim is a Consultant Rheumatologist offering a comprehensive service managing rheumatic conditions in those aged 16 years and above, and including Rheumatoid arthritis, Gout, and other inflammatory arthritic disorder; Back pain, chronic widespread pain; Osteoporosis and Hypermobility and multisystemic complications of the Heritable Disorders of Connective Tissue (HDCTs).

In addition, he has until recently been a Board member in Clinical Commissioning and a Trustee to the UK charity The Hypermobility Syndromes Association. In 2016 Dr Hakim joined the Medical and Scientific Board, The Ehlers-Danlos Society; also the Steering Committee of the International Consortium affiliated to The Ehlers-Danlos Society; and in July ’18 was appointed their Director of Education.

Dr Lori Tucker

Dr. Lori B. Tucker, MD is a Rheumatologist that deals with Fibromyalgia patients out of her office in Vancouver, BC.

My clinical research focus areas include prediction of outcomes for children with juvenile idiopathic arthritis and improving care through longitudinal outcomes registries, the study of physical activity in children with juvenile idiopathic arthritis, the transition of youth with rheumatic disease to adult care, and translational research in autoinflammatory disease.   The strong partnerships of our Division of Pediatric Rheumatology as well as pan-Canadian collaborators in the Canadian Alliance for Pediatric Rheumatology Investigators fuel my research projects and ensure successful translation of research results to practice.  I have a particular interest in creative knowledge translation in pediatric rheumatology research and active inclusion of patients and families into research.

Professor David Jayne

David Jayne is Professor of Clinical Autoimmunity at the School of Clinical Medicine, University of Cambridge, UK. His research group conducts clinical trials and biomarker studies in vasculitis and lupus. He is the Director of the Vasculitis and Lupus Clinic and President of the European Vasculitis Society.

Professor Douglas Veale

Douglas J. Veale is a Professor of Medicine, Director of Translational Research at DAMC, Consultant Rheumatologist and Head of the EULAR Centre of Excellence at St Vincent’s University Hospital, Dublin and Fellow of The Conway Institute for Biomedical and Biomolecular Research, University College Dublin (UCD) and Royal College of Physicians in Ireland and London.

Professor Veale’s primary research interests include Psoriatic and early Rheumatoid arthritis and novel biopharmaceutical therapy.

Professor David Cabral

Professor David Cabral trained in medicine at the University of Western Australia.  He did specialty training in pediatrics and rheumatology both in Western Australia, and then Vancouver where he trained with Dr. Ross Petty.  He joined the British Columbia Children’s Hospital (BCCH) rheumatology team 1992 and took over as Head the Division of Rheumatology in 2004.  His vision has been to integrate research with clinical care and teaching.  He co-founded the Young Adult Rheumatic Disease (YARD) clinic, the first chronic disease transition clinic at BCCH in 1992, and a model for other pediatric rheumatology programs across the country.  His diverse research interests include the study of juvenile idiopathic arthritis and pediatric vasculitis, and he has participated in or helped establish, national and international physician networks and patient registries for the study of children with rheumatic disease.  Most recently he has helped establish a basic science research laboratory for pediatric rheumatology within the BCCH Research Institute.

Professor Ernest Choy

Professor Ernest Choy is Head of Rheumatology and Translational Research at the Institute of Infection and Immunity and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine, Cardiff, Wales, UK. He is also Honorary Consultant Rheumatologist at University Hospital of Wales and Clinical Lead of the Welsh Arthritis Research Network (WARN). Previously, he was Reader and Director of the King’s Musculoskeletal Clinical Trials Unit in the Academic Department of Rheumatology, King’s College London. His major research interest is the treatment of rheumatic diseases focusing on the efficacy of new treatment strategies. He was Director of Research and Development at King’s College Hospital between 2003-2008.

Prof Choy chaired the EULAR Taskforce on developing recommendations for management and classification criteria for fibromyalgia in 2007. Prof Choy has served as a clinical expert to the National Institute for Clinical Excellence in the UK and many pharmaceutical companies. He has published widely on treatments for rheumatic diseases in major medical journals such as the New England Journal of Medicine. He is a frequent lecturer on the treatment of rheumatic diseases.